Dim Velkov Tonev’s Post

🌟 Exciting news from Annals of Hepatology! 🌟 📚 Our latest online publication, "Pathophysiology of Ascites: The Importance of the Intestine. A Surgical Contribution to the Understanding of a Medical Problem" by Gabriel Gondolesi, is now available! 🔍 Dive into this groundbreaking article where the pathophysiology of ascites formation is redefined. Discover how the intestine emerges as a game changer in understanding ascites production. 👩⚕️ Join us in exploring this innovative perspective on ascites and its implications for hepatology. Read the full (free) article here: https://lnkd.in/gWn_b3Rb #Ascites #Hepatology #MedicalResearch #InnovativeInsights #GameChanger 📝💡🔬

Recently, I had the privilege of meeting a woman who spent decades awaiting a diagnosis for metabolic dysfunction-associated steatohepatitis (MASH), a chronic liver disease. This is not just her story. More than 115 million people around the world are living with MASH. Why should we pay attention to this? Due to progressive liver damage that can develop silently, MASH can often go undiagnosed for years. MASH is projected to become the leading cause of liver transplantation by 2030. Each delayed diagnosis is a missed opportunity for early intervention and improved patient outcomes. This underscores the urgent need for innovation in MASH. It is through such advancements that we could transform patient stories from journeys of uncertainty to narratives of hope and healing. Let's continue to push the boundaries of what's possible in healthcare, for the sake of patients worldwide. Today’s announcement of potential best-in-class data is pivotal in our mission to improve the lives of people living with MASH and liver fibrosis. I’m proud of the team for achieving this critical Phase II milestone! #EASLCongress #liverdisease #NEWS

Eli Lilly and Company's tirzepatide, known under the brand names Mounjaro and Zepbound, has shown promising results in treating fatty liver disease in a recent midstage trial. This challenging condition, currently lacking an FDA-approved therapy, saw impressive clearance rates of metabolic dysfunction-associated steatohepatitis (MASH) in overweight or obese adults with no worsening of liver scarring after 52 weeks of treatment.   The results come from the Phase 2 SYNERGY-NASH trial, from a high dose of tirzepatide, 15 mg, given under the skin once per week. Clearance rates for all doses were significantly above the placebo group rate.   Read More: https://lnkd.in/g87Czmuy   #EliLilly #Gastroenterology #MASH #NASH #MAFLD #tirzepatide

We are excited to announce the LifePort Liver Transporter PILOT clinical trial manuscript has been accepted for publication and is now available online! This US multicenter, randomized, non-inferiority trial led by Dr James V Guarrera sought to compare liver preservation using the LLT to the standard of care, static cold storage. The study included 142 liver transplant procedures from 9 US centers, and compared outcomes such as early allograft dysfunction, L-GrAFT7 score, primary nonfunction, biliary strictures, and non-anastomotic biliary strictures. Overall, they concluded that HMP-O2 with LifePort Liver Transporter is safe and efficacious for liver graft preservation compared to SCS. Read the full article here: https://bit.ly/3THimZl

Hepatology experts IHEP (International Hepatology Education Program) explore the potential impact of concomitant use of GLP-1 receptor agonists for the better management of non-alcoholic fatty liver disease. Download the article to learn more: https://bit.ly/3vLfgJM #AvalereHealth #Hepatology #MedicalInnovation #MASH #NASH #GLP1 #ClinicalTrials

Here's what UCSD GI and Hepatology is doing at #TLMAASLD2023

Join us tomorrow for this webinar on “Ensuring those w Hepatitis B are Involved with Guideline Development”! Should the input and perspective of people affected by hepatitis B be part of guideline development? If so, how? Can lived experience be captured to improve guidelines? How do we assess patients’ values and preferences in treatment? Really looking forward this discussion tomorrow. Join us if you want to learn and add to the conversation! Hepatitis B Foundation Danjuma K. Adda Kenneth Kabagambe Catherine Freeland Camilla Graham, MD, MPH Wendy Lo The World Hepatitis Alliance World Health Organization

If you have not heard about the Global NASH Council, which includes a group of 140 international leaders in MASLD and MASH, this data will impress you. "The Global NASH Council (GNC) and Global Liver Council members have consistently demonstrated exceptional academic productivity, producing a substantial body of high-impact evidence in liver disease and NAFLD/MASLD. Our influential work has not only garnered widespread recognition but has also inspired and influenced the research directions. In the latest data from ScholarGPS (2022), our members have been ranked at the top of the field of liver disease, NAFLD, fatty liver disease and hepatology. Highly Ranked Scholars™-Lifetime are eminent authors whose Top Percentage Ranks places them above 0.05% of all scholars due to highly significant impact and quality of their scholarly contributions based on lifetime contributions." Ranking Scholar Report: #1 Zobair Younossi #2 Arun Sanyal #11 Elisabetta Bugianesi #16 Stephen A. Harrison #22 Giulio Marchesini #26 Luca Valenti #28 Rohit Loomba #34 Quentin M. Anstee #35 Kenny Cusi #36 Jacob George #39 Jian-Gao Fan #50 Massimo Colombo #51 Michael Trauner #58 Yusuf Yilmaz

Who Requires a Liver Transplant? (Kashmiri) | Dr. Naveen Ganjoo | Hepatology | Aster RV Dr. Naveen Ganjoo, Senior Consultant in Hepatology & Integrated Liver Care at Aster RV Hospital, discusses the circumstances and individuals who may require a liver transplant. Tune in to gain insights into this crucial topic. To learn more, watch the full video!  https://lnkd.in/dTt_RzHb #LiverTransplant #GetaLiverTransplant #LiverHealth #HepatologyInsights #LiverCare #MedicalAwareness #HealthcareConsultation #LiverDiseaseAwareness #AsterRV #AsterBangalore #AsterHospitals

Well Done 👏 Congratulations 👏 🎊 💐 Wishing You All The Best Continuous Success in #Clinical_Microbiome_Sciences 💜 Let's Start Today before Tomorrow Working Together on: #drkayasseh_IBD_RSM: ● Clinical Scores ● Advanced Novel Bio-Microbiomic Scores => #IBD_Microbiome_Signature      #IBD_Microbiome_Based_Diagnostic_Tools ● Advanced Novel Bio-Imaging Scores ● Advanced Novel Therapeutic Response Rate Scores => #IBD_Microbiome_Based_Therapeutic_Tools